/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Passage Bio Inc Share Price Today: Live Updates & Key Insights

Passage Bio Inc share price today is $7.57, up 0.68%. The stock opened at $7.47 against the previous close of $7.38, with an intraday high of $7.48 and low of $7.3.

Passage Bio Inc Share Price Chart

style
pb-0

Passage Bio Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Passage Bio Inc Share Price Performance

$7.57 0.0068(0.68%) PASG at 23 Mar 2026 02:40 PM Biotechnology
Lowest Today 7.3
Highest Today 7.48
Today’s Open 7.47
Prev. Close 7.38
52 Week High 20.00
52 Week Low 5.12
Day’s Range: Low 7.3 High 7.48
52-Week Range: Low 5.12 High 20.00
1 day return -
1 Week return +0.41
1 month return -19.71
3 month return -25.73
6 month return -1.61
1 year return +1331.36
3 year return +566.36
5 year return -61.19
10 year return -

Passage Bio Inc Institutional Holdings

Lynx1 Capital Management, LP 19.44

Vestal Point Capital LP 9.51

Vanguard Group Inc 3.95

Renaissance Technologies Corp 3.40

Erste Asset Management GmbH 2.66

Vanguard Total Stock Mkt Idx Inv 2.46

TANG CAPITAL MANAGEMENT LLC 2.34

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Geode Capital Management, LLC 0.98

BlackRock Inc 0.93

Acadian Asset Management LLC 0.80

Citadel Advisors Llc 0.55

Quadrature Capital Limited 0.39

Squarepoint Ops LLC 0.34

Fiduciary Trust Co 0.34

NANO CAP NEW MILLENNIUM GROWTH FUND L P 0.31

Fidelity Extended Market Index 0.25

NT Ext Equity Mkt Idx Fd - L 0.25

Fidelity Total Market Index 0.20

NT Ext Equity Mkt Idx Fd - NL 0.19

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.15

Blackrock Extended Mkt Fund CF 0.13

Fidelity Series Total Market Index 0.12

Extended Equity Market Fund K 0.12

Spartan Extended Market Index Pool F 0.10

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.10

ERSTE STOCK BIOTEC EUR R01 A 0.09

Spartan Total Market Index Pool G 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.05

Dimensional US Core Equity 1 ETF 0.04

Dimensional US Core Equity 2 ETF 0.02

DFA US Micro Cap I 0.02

Blackrock US Eq Mkt Fund CF 0.02

Vanguard U.S. Eq Idx £ Acc 0.02

Rockefeller Capital Management L.P. 0.02

Morgan Stanley - Brokerage Accounts 0.01

Barclays PLC 0.01

SBI Securities Co Ltd 0.00

Citigroup Inc 0.00

JPMorgan Chase & Co 0.00

Passage Bio Inc Market Status

Strong Buy: 5

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Passage Bio Inc Fundamentals

Market Cap 23.83 M

PB Ratio 1.2323

PE Ratio 0.0

Enterprise Value 1.38 M

Total Assets 62.28 M

Volume 97988

Passage Bio Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-112375000 -112.4M, FY22:-136856000 -136.9M, FY21:-191500000 -191.5M, FY20:-111762000 -111.8M, FY19:-54579000 -54.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-200000 -0.2M, Q1/2025:-201000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-800000 -0.8M

Quarterly Net worth Q3/2025:-7749000 -7.7M, Q2/2025:-9385000 -9.4M, Q1/2025:-15405000 -15.4M, Q3/2024:-19340000 -19.3M, Q2/2024:-15991000 -16.0M

About Passage Bio Inc & investment objective

Company Information Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Dr. William Chou M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Passage Bio Inc FAQs

What is the share price of Passage Bio Inc today?

The current share price of Passage Bio Inc is $7.57.

Can I buy Passage Bio Inc shares in India?

Yes, Indian investors can buy Passage Bio Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Passage Bio Inc shares in India?

You can easily invest in Passage Bio Inc shares from India by:

Can I buy fractional shares of Passage Bio Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Passage Bio Inc?

Passage Bio Inc has a market cap of $23.83 M.

In which sector does Passage Bio Inc belong?

Passage Bio Inc operates in the Biotechnology sector.

What documents are required to invest in Passage Bio Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Passage Bio Inc?

The PE ratio of Passage Bio Inc is N/A and the PB ratio is 1.23.